Evidence map›Paper›PMID 17003506›Full record

ReviewImmunologic research2006

NKR-P1 biology: from prototype to missing self.

Aruz Mesci, Belma Ljutic, Andrew P Makrigiannis, James R Carlyle

Abstract readReview
PubMed Publisher
In one paragraph

Review in Immunologic research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Review
  3. The proportion of CD161 on CD56Immunity, inflammation and disease · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Structure of the H107R variant of the extracellular domain of mouse NKR-P1A at 2.3 Å resolution.Acta crystallographica. Section F, Structural biology and crystallization communications · 2011
    Article
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Aruz MesciDepartment of Immunology, University of Toronto, Sunnybrook & Women's Research Institute, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada.
Belma Ljutic
Andrew P Makrigiannis
James R Carlyle

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer (NK) cells represent lymphocytes of the innate immune system capable of recognizing and destroying a broad array of target cells, including tumors, virus-infected cells, antibodycoated cells, foreign transplants, and "stressed" cells. NK cells eliminate their targets through two main effector mechanisms, cytokine secretion and cell-mediated cytotoxicity, which in turn depend on detection of target cells through a complex integration of stimulatory and inhibitory receptor-ligand interactions. The NKR-P1 molecules were the first family of NK cell receptors identified, yet they have remained enigmatic in their contribution to self-nonself discrimination until recently. Here, we outline a brief history of the NKR-P1 receptor family, then examine recent data providing insight into their genetic regulation, signaling function, cognate ligands, and gene organization and diversity.

Indexed as

AnimalsAntigens, SurfaceEnhancer Elements, GeneticKiller Cells, NaturalLectins, C-TypeMiceNK Cell Lectin-Like Receptor Subfamily BPromoter Regions, GeneticAntigens, SurfaceLectins, C-TypeNK Cell Lectin-Like Receptor Subfamily B

Identifiers

PMID17003506

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.